Cargando…

PCSK9 inhibitor inclisiran for treating atherosclerosis via regulation of endothelial cell pyroptosis

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) belongs to an intracellular invertase or decarboxylase and is an independent risk factor for atherosclerosis (AS). This study aimed to investigate the therapeutic potential of the PCSK9 inhibitor, inclisiran, and its underlying mechan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kong, Ni, Xu, Qin, Cui, Wei, Feng, Xiaoying, Gao, Huijie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761140/ https://www.ncbi.nlm.nih.gov/pubmed/36544639 http://dx.doi.org/10.21037/atm-22-4652

Ejemplares similares

The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function
por: Di Costanzo, Assunta, et al.
Publicado: (2023)

Inclisiran—Safety and Effectiveness of Small Interfering RNA in Inhibition of PCSK-9
por: Wołowiec, Łukasz, et al.
Publicado: (2023)

PCSK9 Inhibitor Wars: How Does Inclisiran Fit in with Current Monoclonal Antibody Inhibitor Therapy? Considerations for Patient Selection
por: Arnold, Natalie, et al.
Publicado: (2022)

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review
por: Merćep, Iveta, et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

An Update on the Role of PCSK9 in Atherosclerosis
por: Yurtseven, Ece, et al.
Publicado: (2020)

The Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) Perspectives on the Usage of Inclisiran
por: Elserafy, Ahmed Shawky, et al.
Publicado: (2022)

PCSK9 deficiency reduces atherosclerosis, apolipoprotein B secretion, and endothelial dysfunction
por: Sun, Hua, et al.
Publicado: (2018)

Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
por: Sinning, David, et al.
Publicado: (2020)

Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

PCSK9 mediates the oxidative low-density lipoprotein-induced pyroptosis of vascular endothelial cells via the UQCRC1/ROS pathway
por: Zeng, Junfa, et al.
Publicado: (2021)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022)

Correction to: Inclisiran: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

New developments in atherosclerosis: clinical potential of PCSK9 inhibition
por: Giunzioni, Ilaria, et al.
Publicado: (2015)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
por: Punch, Emily, et al.
Publicado: (2022)

The AAV-PCSK9 murine model of atherosclerosis and metabolic dysfunction
por: Keeter, William Coles, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

Interactions between PCSK9 and NLRP3 inflammasome signaling in atherosclerosis
por: Wang, Yanan, et al.
Publicado: (2023)

Nicotine promotes atherosclerosis via ROS-NLRP3-mediated endothelial cell pyroptosis
por: Wu, Xianxian, et al.
Publicado: (2018)

Inclisiran—Silencing the Cholesterol, Speaking up the Prognosis
por: Rogula, Sylwester, et al.
Publicado: (2021)

Inclisiran: a novel drug for the treatment of dyslipidemia
por: Nadeem, Abdullah, et al.
Publicado: (2023)

Aerobic Exercise Training Inhibits Neointimal Formation via Reduction of PCSK9 and LOX-1 in Atherosclerosis
por: Li, Wei, et al.
Publicado: (2020)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

Hydroxytyrosol Acetate Inhibits Vascular Endothelial Cell Pyroptosis via the HDAC11 Signaling Pathway in Atherosclerosis
por: Yao, Feng, et al.
Publicado: (2021)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Ticagrelor suppresses oxidized low-density lipoprotein-induced endothelial cell apoptosis and alleviates atherosclerosis in ApoE(−/−) mice via downregulation of PCSK9
por: Xia, Xiaodong, et al.
Publicado: (2019)

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2019)

PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
por: Momtazi-Borojeni, Amir Abbas, et al.
Publicado: (2021)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

PCSK9 activation promotes early atherosclerosis in a vascular microphysiological system
por: Lee, Jounghyun H., et al.
Publicado: (2023)

Pyrroloquinoline quinone inhibits PCSK9-NLRP3 mediated pyroptosis of Leydig cells in obese mice
por: Wang, Jinyuan, et al.
Publicado: (2023)

Role of PCSK9 in Homocysteine-Accelerated Lipid Accumulation in Macrophages and Atherosclerosis in ApoE(−/−) Mice
por: Jin, Ping, et al.
Publicado: (2021)

Efficacy and safety of inclisiran in patients with cerebrovascular disease: ORION-9, ORION-10, and ORION-11
por: Koenig, Wolfgang, et al.
Publicado: (2023)

Egyptian Association of Vascular Biology and Atherosclerosis (EAVA) consensus on the usage of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
por: Reda, Ashraf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9gdu5nv576k10driage0j3farj